Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Placental Mitochondrial Function and Dysfunction in Preeclampsia

Version 1 : Received: 27 January 2023 / Approved: 30 January 2023 / Online: 30 January 2023 (04:33:29 CET)
Version 2 : Received: 9 February 2023 / Approved: 10 February 2023 / Online: 10 February 2023 (04:09:05 CET)

A peer-reviewed article of this Preprint also exists.

Jahan, F.; Vasam, G.; Green, A.E.; Bainbridge, S.A.; Menzies, K.J. Placental Mitochondrial Function and Dysfunction in Preeclampsia. Int. J. Mol. Sci. 2023, 24, 4177. Jahan, F.; Vasam, G.; Green, A.E.; Bainbridge, S.A.; Menzies, K.J. Placental Mitochondrial Function and Dysfunction in Preeclampsia. Int. J. Mol. Sci. 2023, 24, 4177.

Abstract

The placenta is a vital organ of pregnancy, regulating adaptation to pregnancy, gestational-parent/fetal exchange and ultimately fetal development and growth. Not surprisingly, in cases of placental dysfunction - where aspects of placental development or function become compromised - adverse pregnancy outcomes can result. One common placenta-mediated disorder of pregnancy is preeclampsia (PE), a hypertensive disorder of pregnancy with a highly heterogeneous clinical presentation. The wide array of clinical characteristics observed in pregnant individuals and neonates of a PE pregnancy are likely the result of distinct forms of placental pathology underlying the PE diagnosis, explaining why no one common intervention has proven effective in the prevention or treatment of PE. The historical paradigm of placental pathology in PE highlights an important role for utero-placental malperfusion, placental hypoxia and oxidative stress, and a critical role for placental mitochondrial dysfunction in the pathogenesis and progression of the disease. In the current review, the evidence of placental mitochondrial dysfunction in the context of PE will be summarized, highlighting how altered mitochondrial function may be a common feature across distinct PE subtypes. Further, advances in this field of study and therapeutic targeting of mitochondria as a promising intervention for PE will be discussed.

Keywords

placenta; mitochondria; preeclampsia; disease subclasses; pregnancy; hypertension; reactive oxygen species; therapies

Subject

Medicine and Pharmacology, Obstetrics and Gynaecology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.